Physician profile
Ryan Patrick Werntz
NPI 1780940023
$14,561.91
in general payments reported to CMS, 2019-2025
21 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $613 · 2021: $9,562 · 2022: $2,028 · 2023: $1,679 · 2024: $102 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,313 · Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,312.50 |
| Food and Beverage | $726.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photocure INC | $12,382.07 | 2019-2023 | Cysview |
| Karl Storz Endoscopy-America | $293.28 | 2019-2021 | |
| Coloplast Corp | $286.31 | 2020-2024 | Speedicath |
| Neotract INC. | $266.45 | 2020 | |
| Urogen Pharma, INC. | $216.90 | 2022-2025 | |
| Procept Biorobotics Corporation | $189.01 | 2023 | Aquabeam Robotic System |
| Bayer Healthcare Pharmaceuticals INC. | $142.65 | 2019-2023 | |
| Boston Scientific Corporation | $130.61 | 2022 | |
| Olympus America INC. | $125.60 | 2020 | |
| Davol INC. | $125.00 | 2025 | |
| Intuitive Surgical, INC. | $101.67 | 2022-2024 | |
| Astellas Pharma US INC | $52.70 | 2019 | |
| Merck Sharp & Dohme LLC | $43.50 | 2019 | |
| Janssen Biotech, INC. | $39.39 | 2025 | Erleada |
| Ferring Pharmaceuticals INC. | $35.83 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $35.76 | 2024 | |
| Immunitybio, INC. | $28.07 | 2025 | |
| Abbvie INC. | $26.38 | 2025 | |
| Smith+Nephew, INC. | $24.96 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $15.77 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Werntz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.